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Letter to the Editor
Dear Dr. Walson:
With great interest we read the paper by Kang et al1 on the analgesic effects of keta-
mine infusion therapy in Korean patients with neuropathic pain.
Since 1994, various articles based on case reports, pilot studies, and clinical trials 
have documented the value and tolerability of ketamine for the treatment of neuro-
pathic pain states.2
Due to its unique mechanism of action, ketamine is a highly interesting drug for 
treatment-resistant neuropathic pain syndromes, administered via various routes. 
Long periods of decreased pain can be triggered by relatively short courses of infusion. 
Dutch anesthesiologists found that complex regional pain syndrome type 1 (CRPS-1) 
patients with severe pain treated for 4 days with a continuous infusion of low-dose 
S-ketamine (N = 30) had a clinically relevant and statistically significant reduction in 
pain lasting for up to 11 weeks compared with patients receiving placebo (P < 0.001). 
However, one of the troublesome clinical aspects of treatment using intravenous 
ketamine is the reemergence of pain after some weeks and, therefore, the necessity to 
readminister treatment.3
Various topical racemic ketamine formulations, such as gels, ointments, and creams, 
in a dose range from 0.25% to 10.0%, have been compounded, and the efficacy and 
tolerability has been documented in a number of papers.4–7 In a 2009 double-blind, 
placebo-controlled, crossover study, ketamine 10% in pluronic lecithin organogel was 
associated with alleviating allodynia in CRPS-1 patients without detectable blood 
levels of ketamine.8 This might suggest a topical mechanism of action, or a suboptimal 
dose regimen.
In our clinic, we gained experience prescribing 10% racemic ketamine cream in 
CRPS-1 patients with treatment-refractory pain. Anecdotally, we have noted signifi-
cant pain reduction with this intervention without additional adverse effects, including 
without negative effects on blood pressure. Well-designed studies evaluating the use 
of a topical 10% ketamine cream are necessary, as such treatment may be more easily 
tolerated and less expensive than ketamine infusion therapy.
Jan M. Keppel Hesselink, MD, MSc, PhD
David J. Kopsky, MD
Institute for Neuropathic Pain
Soest, The Netherlands
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